A Study in People With Overweight or Obesity to Compare How 2 Different Formulations of Survodutide Are Taken up by the Body
Boehringer Ingelheim · Healthy · Obesity
Phase 1
Recruiting
80
2026-07
Industry sponsor intelligence
Boehringer IngelheimClinical Pipeline.
Lead-sponsor view of Boehringer Ingelheim's indexed peptide studies, development phases, active programs, completed work and recent registry changes.
- Total
- 32
- Recruiting
- 3
- Active
- 3
- Completed
- 25
- Results posted
- 4
- Avg enrollment
- 430
Pipeline overview
Programs by phase and activity.
Velocity
Boehringer Ingelheim trials by start year
Study start year · indexed snapshot
Development
Trials by phase
31phase labels
Early Phase 10
Phase 119
Phase 23
Phase 39
Phase 40
| Product | Studies | Early / I | Phase II | Phase III | Phase IV | Active |
|---|---|---|---|---|---|---|
| Survodutide → | 30 | 19 | 3 | 8 | 0 | 6 |
| Enfuvirtide → | 1 | 0 | 0 | 1 | 0 | 0 |
| Glucagon → | 2 | 1 | 0 | 0 | 0 | 1 |
| Semaglutide → | 1 | 1 | 0 | 0 | 0 | 1 |
Active peptide trials
In motion now.
NCT IDStudyPhase / statusEnrollmentUpdated
A Study in People With Obesity to Test the Effects of BI 456906 Compared With Semaglutide on Glucagon Receptor Activity in the Liver
Boehringer Ingelheim · Obesity
Phase 1
Active, not recruiting
29
2026-07
LIVERAGE™: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Moderate or Advanced Liver Fibrosis
Boehringer Ingelheim · Metabolic Dysfunction Associated Steatohepatitis (MASH) · Liver Fibrosis
Phase 3
Recruiting
1,800
2026-07
LIVERAGE™ - Cirrhosis: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Cirrhosis
Boehringer Ingelheim · Metabolic Dysfunction Associated Steatohepatitis
Phase 3
Recruiting
1,590
2026-07
A Study to Test Whether Survodutide Improves How the Body Uses Energy and Breaks Down Fat in People With Obesity
Boehringer Ingelheim · Obesity
Phase 1
Active, not recruiting
64
2026-05
A Study in Healthy People to Compare How 2 Different Formulations of Survodutide Are Taken up by the Body
Boehringer Ingelheim · Healthy
Phase 1
Active, not recruiting
100
2026-03
Completed trials
Finished registry records.
NCT IDStudyPhase / statusEnrollmentUpdated
A Study to Test the Effect of Survodutide (BI 456906) on Cardiovascular Safety in People With Overweight or Obesity (SYNCHRONIZE™ - CVOT)
Boehringer Ingelheim · Obesity
Phase 3
Completed
5,531
2026-07
Comparative Effectiveness of Empagliflozin in the US
Boehringer Ingelheim · Diabetes Mellitus, Type 2
Not applicable
Completed
230,000
2026-07
A Study to Test Whether Survodutide (BI 456906) Helps People Living With Overweight or Obesity Who Also Have Diabetes to Lose Weight
Boehringer Ingelheim · Obesity · Diabetes Mellitus, Type 2
Phase 3
Completed
755
2026-06
A Study in Healthy People or Otherwise Healthy With Overweight or Obesity to Compare 2 Formulations of Survodutide Given in Different Ways, Either as a Pre-filled Syringe or a Pen-like Injector
Boehringer Ingelheim · Healthy · Obesity
Phase 1
Completed
56
2026-06
A Study to Test Whether Survodutide Helps Japanese People Living With Obesity Disease
Boehringer Ingelheim · Obesity
Phase 3
Completed
274
2026-04
A Study to Test Whether Survodutide (BI 456906) Helps Chinese People Living With Overweight or Obesity to Lose Weight
Boehringer Ingelheim · Obesity · Overweight
Phase 3
Completed
307
2026-04
A Study to Test Whether Survodutide Helps People Living With Obesity or Overweight and With a Confirmed or Presumed Liver Disease Called Non-alcoholic Steatohepatitis (NASH) to Reduce Liver Fat and to Lose Weight (SYNCHRONIZE-MASLD)
Boehringer Ingelheim · Obesity · Non-Alcoholic SteatoHepatitis (NASH)
Phase 3
Completed
218
2026-04
A Study to Test Whether Multiple Doses of BI 456906 Have an Effect on Cardiac Safety in People With Overweight or Obesity
Boehringer Ingelheim · Overweight · Obesity
Phase 1
Completed
110
2026-03
A Study to Test How BI 456906 is Taken up in the Blood of People With and Without Kidney Problems
Boehringer Ingelheim · Healthy · Renal Impairment
Phase 1
Completed
42
2026-03
A Study to Test Whether BI 456906 (Survodutide) Influences the Amount of Bupropion, Caffeine and Midazolam in the Blood in People With Overweight or Obesity
Boehringer Ingelheim · Overweight · Obesity
Phase 1
Completed
34
2026-03
Showing 10 of 25 studies
Search sponsor records
All Boehringer Ingelheim studies.
This page groups studies where Boehringer Ingelheim is listed as the lead industry sponsor. Collaborator-only records are not included in the count.
32 matching studies
Last registry update first
Recent updates
Latest registry movement.
NCT07407348A Study in People With Overweight or Obesity to Compare How 2 Different Formulations of Survodutide Are Taken up by the BodyJul 30, 2026NCT06077864A Study to Test the Effect of Survodutide (BI 456906) on Cardiovascular Safety in People With Overweight or Obesity (SYNCHRONIZE™ - CVOT)Jul 23, 2026NCT03363464Comparative Effectiveness of Empagliflozin in the USJul 22, 2026NCT05202353A Study in People With Obesity to Test the Effects of BI 456906 Compared With Semaglutide on Glucagon Receptor Activity in the LiverJul 22, 2026NCT06632444LIVERAGE™: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Moderate or Advanced Liver FibrosisJul 9, 2026NCT06632457LIVERAGE™ - Cirrhosis: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have CirrhosisJul 9, 2026NCT06066528A Study to Test Whether Survodutide (BI 456906) Helps People Living With Overweight or Obesity Who Also Have Diabetes to Lose WeightJun 24, 2026NCT07413913A Study in Healthy People or Otherwise Healthy With Overweight or Obesity to Compare 2 Formulations of Survodutide Given in Different Ways, Either as a Pre-filled Syringe or a Pen-like InjectorJun 15, 2026NCT06745284A Study to Test Whether Survodutide Improves How the Body Uses Energy and Breaks Down Fat in People With ObesityMay 12, 2026NCT06176365A Study to Test Whether Survodutide Helps Japanese People Living With Obesity DiseaseApr 30, 2026